Paper Details
- Home
- Paper Details
Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
Author: AtzoriLaura, MughedduCristina, PizzattiLaura, RongiolettiFranco, SannaSilvia
Original Abstract of the Article :
Erythrodermic psoriasis is a severe, life-threatening condition with additional complications, when occurring in hemodialyzed patients, as the majority of treatments are contraindicated. A 44-years-old man, of Philippine origins, with a 15-years-history of psoriasis treated with cyclosporine develop...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1111/dth.13348
データ提供：米国国立医学図書館（NLM）
Erythrodermic Psoriasis: A Desert of Treatment Options
Erythrodermic psoriasis is a severe and often debilitating skin condition, characterized by widespread inflammation and scaling. This study explores the effectiveness of secukinumab, a targeted therapy, in treating erythrodermic psoriasis in a hemodialyzed patient, highlighting its potential as a safe and effective treatment option for patients with limited therapeutic choices. The researchers report a case of a 44-year-old man with erythrodermic psoriasis and end-stage renal failure, who achieved a significant improvement in his skin condition after receiving secukinumab treatment.
A Beacon of Hope: Secukinumab for Erythrodermic Psoriasis in Hemodialyzed Patients
This case report offers a beacon of hope for patients with erythrodermic psoriasis, particularly those with limited treatment options due to underlying conditions. It’s a reminder that innovative therapies can provide significant relief and improve quality of life for patients facing challenging skin conditions. The study’s findings suggest that secukinumab can be a valuable therapeutic tool, offering a potential path to remission for patients with erythrodermic psoriasis.
Navigating the Desert of Skin Disease: A New Path for Erythrodermic Psoriasis Treatment
This study highlights the potential of secukinumab in treating erythrodermic psoriasis, a severe and often challenging skin condition. It’s a reminder that advancements in dermatological research are providing new and effective treatments for patients struggling with skin diseases. The study’s findings offer a promising pathway for improving the management of erythrodermic psoriasis, offering hope for a brighter future for patients with this debilitating condition.
Dr. Camel's Conclusion
This case report provides valuable insights into the effectiveness of secukinumab in treating erythrodermic psoriasis, a challenging skin condition. It’s a reminder that advancements in dermatological research are providing new and effective treatments, offering hope for a brighter future for patients struggling with skin diseases.
Date :
- Date Completed 2021-05-14
- Date Revised 2021-05-14
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.